Irbinitinib NEW

Email: sales@anbuchem.com

Whatsapp:+8618638608485

24 hours online, Welcom to inquiry.

Irbinitinib Basic information

Product Name: Irbinitinib

Synonyms: ONT-380);N4-(4-([1;4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-;N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;Irbinitinib;Irbinitinib(ARRY380);Irbinitinib (ARRY-380,Tucatinib,ONT 380);IRBINITINIB (ARRY-380; ONT-380)

CAS: 937263-43-9

MF: C26H24N8O2

MW: 480.52

EINECS: 200-001-8

Product Categories: Inhibitors;API

Mol File: 937263-43-9.mol

Irbinitinib Structure

Irbinitinib Chemical Properties

density 1.41±0.1 g/cm3(Predicted)

storage temp. Store at -20°C

solubility DMF:1.0(Max Conc. mg/mL);2.08(Max Conc. mM)

DMSO:49.0(Max Conc. mg/mL);101.97(Max Conc. mM)

DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.69(Max Conc. mM)

form A crystalline solid

pka 6.61±0.70(Predicted)

InChIKey SDEAXTCZPQIFQM-UHFFFAOYSA-N

SMILES N1=C2C(C=C(NC3=NC(C)(C)CO3)C=C2)=C(NC2=CC=C(OC3C=CN4N=CN=C4C=3)C(C)=C2)N=C1

Safety Information

MSDS Information

Irbinitinib Usage And Synthesis

Description Irbinitinib is also known as ARRY-380 or Tucatinib. ARRY-380 is an orally inhibitor of human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. It selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. Therefore, ARRY-380 may be an alternative treatmentmethod for the treatment of HER2+ cancers.

Uses N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine is a novel?diarylamine ErbB inhibitor.

References Lee, P., et al. "In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab." Cancer Research 69.24 Supplement(2009):5104-5104.

Moulder, S. L., et al. "Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation." Molecular Cancer Therapeutics 10.Supplement 1(2011):A143-A143.

Dinkel, Victoria, et al. "Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice." Cancer Research 72.8 Supplement(2012).